MRUS earnings

Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT Genmab A/S (NASDAQ: GMAB) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus, a clinical-stage biotechnology company with its late-st

Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billionProposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT COPENHAGEN, Denmark; UTRECHT, The Netherlands; September 29, 2025, – Genmab A/S (NASDAQ: GMAB) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus,

-  63% response rate observed among 43 evaluable patients -  79% overall survival rate at 12-months; 9 months median progression-free survival -  Conference Call on Thursday, May 22 at 5:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab. These data will be

- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting - Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced financial results for the first quarter and provided a business update. "We are very muc

- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation - Conference call on Thursday, May 22 at 5:30 p.m. ET to discuss full ASCO® data set UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the acceptance of an abstract for presentation at the 2025 American Society of Clinical Oncology® (ASCO®) Annual Meeting, being held in Chicago, Illinois on May 30- June 3, 202

-  Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25 -  Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update planned for 1H25 -  Petosemtamab evaluation in mCRC ongoing in combination with standard chemotherapy in 1L and 2L and monotherapy in 3L+; mCRC initial clinical data planned for 2H25 -  Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2028 UTRECHT, The Netherla

Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025 Petosemtamab in mCRC evaluation expanded to include 1L and 3L+; initial clinical data planned for 2025 – Conference Call on Saturday, December 7th at 9:00 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 07, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced interim clinical data as of a July 5, 2024 data cutoff from the ongoing phase 1/2 trial of petosemtamab, a Biclonics® tar

– Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate clinically meaningful activity in 2L+ HNSCC – Conference call on Saturday, Dec. 7 at 9:00 a.m. ET to discuss full data set UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of an abstract regarding petosemtamab, a Biclonics® targeting EGFR and LGR5, in previously treated (2L+) patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC)

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling Petosemtamab in 2L+ r/m HNSCC interim clinical data accepted for rapid oral presentation at ESMO® Asia Congress 2024 Based on the Company's current operating plan, existing cash, cash equivalents, and marketable securities expected to fund Merus' operations into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) --  Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today

67% response rate observed among 24 evaluable patients Conference Call on Tuesday, May 28th at 8 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced interim clinical data as of a March 6, 2024 data cutoff from the ongoing phase 1/2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab. These data will be presented by Dr. Jerome Fayette M.D. Ph.D., Centre Léon Bérard, Lyon, France at the 2024 American Society of Clinical Oncology® (

-   60% response rate observed among 10 evaluable patients -   Favorable safety profile in 26 patients enrolled as of the abstract cutoff date, with no significant overlapping toxicities observed -   Conference call on Tuesday, May 28 at 8:00 a.m. ET to discuss full ASCO® data set UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of an abstract regarding petosemtamab in combination with pembrolizumab on the 2024 American Society of Clinical Oncol

Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data at 2024 ASCO Annual Meeting; preparing for a potential phase 3 trialZeno BLA accepted for priority review by the FDA for the treatment of NRG1+ NSCLC and PDACBased on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2027 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for

-   Petosemtamab in 1L HNSCC in combination with pembrolizumab initial interim clinical data planned for 2Q24; preparing for a potential phase 3 trial -   Petosemtamab in 2L+ HNSCC phase 3 trial planned to initiate mid-2024; interim clinical data planned for 2H24 -   Petosemtamab in 2L CRC: cohort planned to initiate in 2024 -   Zeno in NRG1+ cancer: Sufficient clinical data expected in 1H24 to support potential BLA submissions -   Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2027 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS)

-  Oral presentation on MCLA-129 in combination with osimertinib as first line therapy, and in previously treated, NSCLC on Sunday, December 3 at 9:40 a.m. SGT  -  Poster presentation on MCLA-129 in previously treated HNSCC on Saturday, December 2 at 17:50 p.m. SGT -  Investor call on Monday, November 27, 2023 8:00 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 26, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of two abstracts regarding MCLA-129 on the European Society for Medical On

Zeno interim clinical data continues to show robust efficacy in NRG1+ NSCLC and PDAC: Sufficient clinical data expected in 1H24 to support potential BLA submissions Petosemtamab 2L+ HNSCC phase 3 trial design supported by INTERLINK-1 control armClinical data update on petosemtamab monotherapy in 2L+ HNSCC planned 2024MCLA-129 abstracts accepted at ESMO AsiaInvestor call on Monday, October 16 at 7:30 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that

– Petosemtamab granted Fast Track Designation for the treatment of patients with recurrent or metastatic head & neck squamous cell carcinoma – Phase 3 trial of petosemtamab monotherapy in previously treated (2L/3L) head and neck squamous cell carcinoma planned to initiate in mid-2024 – Zeno granted two Breakthrough Therapy Designations in NRG1 fusion (NRG1+) non-small cell lung and pancreatic cancer – Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2026 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we,

– Petosemtamab clinical update presented at the American Association of Cancer Research (AACR) Annual Meeting 2023– Petosemtamab end-of-phase meeting with U.S. Food & Drug Administration provides clarity to potential registration path in head and neck squamous cell carcinoma (HNSCC)– Petosemtamab update planned for Q3 2023 on potential registrational path in HNSCC– Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into second half 2025 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology co

- 37% overall response rate (ORR) observed in 43 evaluable patients- 6 months median duration of response as of Feb. 1, 2023 data cutoff date- End-of-phase meeting with U.S. Food & Drug Administration provides clarity to potential registration path in HNSCC- Investor call on April 17, 2023 at 6:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced interim clinical data as of a February 1, 2023 data cutoff, from the ongoing phase 1/2 trial of the

- Robust 36% overall response rate (ORR) in 42 evaluable patients - 6 months median duration of response with 17 patients still on treatment as of Nov. 28, 2022 data cutoff - End-of-Phase meeting with U.S. Food & Drug Administration provides clarity to potential registration path in HNSCC - Investor call on April 17, 2023 at 6:30 p.m. ET ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of an abstract for a plenary session oral presentation

– Plenary session oral presentation: Monday, April 17, 2023, 10:15 a.m.-12:15 p.m. ET– Poster presentation on petosemtamab in advanced gastric/esophageal adenocarcinoma: Monday, April 17, 2023, 1:30-5:30 p.m. ET– Investor call on Monday, April 17, 2023 at 6:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the selection of an abstract for a plenary session oral presentation that will highlight interim clinical data on the bispecific antibody petosemta

– Zenocutuzumab (Zeno) in NRG1+ cancer potential registrational path and timeline update planned for first half of 2023 – Petosemtamab clinical and regulatory update planned for first half of 2023 – MCLA-129 clinical update planned for second half of 2023  – Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into second half 2025 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today ann

– Clinical update of MCLA-129 presented at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics– Zenocutuzumab (Zeno) Regulatory update: FDA recommends additional enrollment in eNRGy trial to support potential BLA filing– Clinical update of petosemtamab planned for first half of 2023 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", the "Company," "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the third quarter that ended September 30, 2022 and provided a bus

- MCLA-129 observed to be well tolerated with a favorable safety profile - Antitumor activity was observed among heavily pretreated patients, across multiple tumor types and dose levels​ - Initial recommended phase 2 dose 1500 mg every two weeks; expansion cohorts enrolling - Investor call to discuss a MCLA-129 program update on October 26 at 13:30 CET/7:30am ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of interi

– MCLA-129 observed to be well tolerated with preliminary evidence of anti-tumor activity during dose escalation phase – Initial recommended phase two dose set at 1500 mg with dose expansion ongoing – Poster presentation with additional data at ENA available on October 26 at 9am CET/3am ET, and presented on October 28, 2022, 10:00-15:00 CET – Investor call to discuss a MCLA-129 program update on October 26 at 13:30 CET/7:30am ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Tri

- Clinical update of zenocutuzumab (Zeno) presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - Zeno represents a potential new standard of care for NRG1+ cancer - Clinical update of MCLA-129 planned for second half of 2022; expansion cohorts including combination with osimertinib planned - Clinical update of petosemtamab (Peto) planned for first half of 2023 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", the "Company," "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial resu

34% overall response rate in 79 evaluable patients with measurable disease9.1 months median duration of responseTumor reduction in 70% of patientsZeno observed to be very well-toleratedPotential new standard of care for patients with NRG1+ cancerInvestor call to discuss clinical results on Sunday, June 5 at 6:00 p.m. CT UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 05, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced interim efficacy data as of an April 12, 2022 data cutoff date, from the phase 1/2 eNRG

- Zenocutuzumab clinical abstract selected for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting- Company to host investor call on Sunday, June 5 at 6:00 p.m. CT- Clinical data update of petosemtamab (Peto) and MCLA-129 planned for second half of 2022 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", the "Company," "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the first quarter that ended March 31, 2022, and provided a business update. "We continue t

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the selection of an abstract for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois on June 3-7, 2022. The presentation will highlight updated interim clinical data for the targeted bispecific antibody, zenocutuzumab (Zeno), in NRG1 fusion positive (NRG1+) cancer. Merus is currently enrolling patients into the phase 1/2 eNRGy trial to

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", the "Company," "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the second quarter that ended June 30, 2021 and provided a business update. "We are encouraged by the interim results on Zeno in patients with NRG1 fusion cancers that we reported in the second quarter and remain focused on successful execution of our Zeno program and our other clinical trials," said Bill Lundberg, M.D., President, Chief Executive Officer of Merus. "We are plannin

Clinical data update on zenocutuzumab selected for oral presentation at ASCO MCLA-145 clinical update planned for 2H21 MCLA-129 first patient dosed in phase 1/2 trial Cecile Geuijen, Ph.D., promoted to Chief Scientific Officer UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", the "Company," "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the first quarter that ended March 31, 2021, and provided a business update. "We have made significant progress on our clinical programs this quarter and we

Clinical data and program update planned for lead program zenocutuzumab (“Zeno”) in 2Q 2021 Clinical update planned for MCLA-145 in 2H 2021 MCLA-129 expected to enter clinic in the United States in 2021 UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided a business update. “We have made significant progress in 2020, advancing our clinical programs, further developing our disco